Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction

European Journal of Medicinal Chemistry

Volumn 80, Issue , 2014, Pages 154-166

  Gogate, Priyanka N ^a   Ethirajan, Manivannan ^a   Kurenova, Elena V ^a,c   Magis, Andrew T ^b   Pandey, Ravindra K ^a   Cance, William G ^a,c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c CureFAKtor Pharmaceuticals   (United States)

Author keywords

FAK scaffold inhibitor; Focal adhesion kinase; Focal adhesion targeting domain; Protein protein interaction; Vascular endothelial growth factor receptor 3

Indexed keywords

FOCAL ADHESION KINASE INHIBITOR; N (4 CHLOROBENZYL)PYRIDIN 2 AMINE; N [(3,5 BIS TRIFLUOROMETHYL PHENYL)METHYL] N [2 (DIMETHYLAMINO)ETHYL]PYRIDIN 2 AMINE; N [(4 BROMOPHENYL)METHYL] N [2 (DIMETHYLAMINO)ETHYL] PYRIDIN 2 AMINE; N [(4 CHLOROPHENYL)METHYL] N [2 (DIMETHYLAMINO)ETHYL] QUINOLIN 2 AMINE; N [(4 CHLOROPHENYL)METHYL] N [2 (DIMETHYLAMINO)ETHYL]PHENYLAMINE; N [(4 CHLOROPHENYL)METHYL] N [2 (DIMETHYLAMINO)PROPYL] PYRIDIN 2 AMINE; N [(4 IODOPHENYL)METHYL] N [2 (DIMETHYLAMINO)ETHYL] PYRIDIN 2 AMINE; N [(4 METHYLTHIOPHENYL)METHYL] N [2 (DIMETHYLAMINO) ETHYL]PYRIDIN 2 AMINE; N [DECYL] N [2 (DIMETHYLAMINO)ETHYL]PYRIDIN 2 AMINE; N [DODECYL] N [2 (DIMETHYLAMINO)ETHYL]PHENYLAMINE; N [DODECYL] N [2 (DIMETHYLAMINO)ETHYL]PYRIDIN 2 AMINE; N [HEXYL] N [2 (DIMETHYLAMINO)ETHYL]PHENYLAMINE; N [HEXYL] N [2 (DIMETHYLAMINO)ETHYL]PYRIDIN 2 AMINE; N [HEXYL] N [2 (DIMETHYLAMINO)ETHYL]QUINOLIN 2 AMINE; N [OCTYL] N [2 (DIMETHYLAMINO)ETHYL]PYRIDIN 2 AMINE; N [PROPYL] N [2 (DIMETHYLAMINO)ETHYL]PYRIDIN 2 AMINE; N, N DIMETHYL N' (PHENYL)ETHANE 1,2 DIAMINE; N, N DIMETHYL N' (PYRIDINE 2 YL)ETHANE 1,2 DIAMINE; N, N DIMETHYL N' (PYRIDINE 2 YL)PROPANE 1,2 DIAMINE; N, N DIMETHYL N' (QUINOLIN 2 YL)ETHANE 1,2 DIAMINE; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 3 INHIBITOR; VASCULOTROPIN INHIBITOR; CHLOROPYRAMINE; ETHYLENEDIAMINE DERIVATIVE; FOCAL ADHESION KINASE; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; VASCULOTROPIN RECEPTOR 3;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; MOLECULAR MODEL; MULTIPLE CANCER; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; CELL DEATH; CHEMISTRY; DRUG EFFECTS; METABOLISM; MOLECULAR DOCKING; PROTEIN CONFORMATION; SYNTHESIS; TUMOR CELL LINE;

CELL DEATH; CELL LINE, TUMOR; CHEMISTRY TECHNIQUES, SYNTHETIC; DRUG DESIGN; ETHYLENEDIAMINES; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; MOLECULAR DOCKING SIMULATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84899583339     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.04.041     Document Type: Article

References (43)

1. J.T. Parsons Focal adhesion kinase: the first ten years Journal of Cell Science 116 2003 1409 1416 (Pubitemid 36527488)
2. M.D. Schaller, C.A. Borgman, B.S. Cobb, R.R. Vines, A.B. Reynolds, and J.T. Parsons pp125fak a structurally distinctive protein-tyrosine kinase associated with focal adhesions Proceedings of the National Academy of Sciences of the United States of America 89 1992 5192 5196
3. J. Zhao, and J.-L. Guan Signal transduction by focal adhesion kinase in cancer Cancer Metastasis Reviews 28 2009 35 49
4. M.C. Frame, H. Patel, B. Serrels, D. Lietha, and M.J. Eck The FERM domain: organizing the structure and function of FAK Nature Reviews. Molecular Cell Biology 11 2010 802 814
5. Y. Shen, and M.D. Schaller Focal adhesion targeting: the critical determinant of FAK regulation and substrate phosphorylation Molecular Biology of the Cell 10 1999 2507 2518 (Pubitemid 29393506)
6. E. Kurenova, L.-H. Xu, X. Yang, A.S. Baldwin Jr., R.J. Craven, S.K. Hanks, Z.-g. Liu, and W.G. Cance Focal adhesion kinase suppresses apoptosis by binding to the death domain of receptor-interacting protein Molecular and Cellular Biology 24 2004 4361 4371 (Pubitemid 41071006)
7. W.G. Cance, E. Kurenova, T. Marlowe, and V. Golubovskaya Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics Science Signalling 6 2013 pe10
8. G.W. McLean, N.O. Carragher, E. Avizienyte, J. Evans, V.G. Brunton, and M.C. Frame The role of focal-adhesion kinase in cancer - a new therapeutic opportunity Nature Reviews. Cancer 5 2005 505 515 (Pubitemid 40942827)
9. A.L. Lark, C.A. Livasy, L. Dressler, D.T. Moore, R.C. Millikan, J. Geradts, M. Iacocca, D. Cowan, D. Little, R.J. Craven, and W. Cance High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc 18 2005 1289 1294 (Pubitemid 41348647)
10. L.V. Owens, L. Xu, R.J. Craven, G.A. Dent, T.M. Weiner, L. Kornberg, E.T. Liu, and W.G. Cance Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors Cancer Research 55 1995 2752 2755
11. D.D. Schlaepfer, S.K. Mitra, and D. Ilic Control of motile and invasive cell phenotypes by focal adhesion kinase Biochimica et Biophysica Acta 1692 2004 77 102 (Pubitemid 38898737)
12. M.J. van Nimwegen, S. Verkoeijen, L. van Buren, D. Burg, and B. van de Water Requirement for focal adhesion kinase in the early phase of mammary adenocarcinoma lung metastasis formation Cancer Research 65 2005 4698 4706 (Pubitemid 40740806)
13. M.S. Duxbury, H. Ito, E. Benoit, M.J. Zinner, S.W. Ashley, and E.E. Whang RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity Biochemical and Biophysical Research Communications 311 2003 786 792 (Pubitemid 37377726)
14. G.W. McLean, N.H. Komiyama, B. Serrels, H. Asano, L. Reynolds, F. Conti, K. Hodivala-Dilke, D. Metzger, P. Chambon, S.G. Grant, and M.C. Frame Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression Genes & Development 18 2004 2998 3003 (Pubitemid 39658168)
15. C.S. Smith, V.M. Golubovskaya, E. Peck, L.H. Xu, B.P. Monia, X. Yang, and W.G. Cance Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines Melanoma Research 15 2005 357 362 (Pubitemid 41558945)
16. V.M. Golubovskaya, F.A. Kweh, and W.G. Cance Focal adhesion kinase and cancer Histology and Histopathology 24 2009 503 510
17. P.M.F. Siesser, and S.K. Hanks The signaling and biological implications of FAK overexpression %R 10.1158/1078-0432.CCR-06-0456 Cancer, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 12 2006 3233 3237
18. A. Schultze, and W. Fiedler Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase Anti-Cancer Agents in Medicinal Chemistry 11 2011 593 599
19. J.T. Hartmann, M. Haap, H.G. Kopp, and H.P. Lipp Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects Current Drug Metabolism 10 2009 470 481
20. G. Oliver Lymphatic vasculature development Nature Reviews. Immunology 4 2004 35 45 (Pubitemid 38084130)
21. P. Saharinen, T. Tammela, M.J. Karkkainen, and K. Alitalo Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation Trends in Immunology 25 2004 387 395 (Pubitemid 38780956)
22. N.R. Smith, D. Baker, N.H. James, K. Ratcliffe, M. Jenkins, S.E. Ashton, G. Sproat, R. Swann, N. Gray, A. Ryan, J.M. Jürgensmeier, and C. Womack Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers Clinical Cancer Research 16 2010 3548 3561
23. Y. He, I. Rajantie, K. Pajusola, M. Jeltsch, T. Holopainen, S. Yla-Herttuala, T. Harding, K. Jooss, T. Takahashi, and K. Alitalo Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels Cancer Research 65 2005 4739 4746 (Pubitemid 40740810)
24. T. Karpanen, M. Egeblad, M.J. Karkkainen, H. Kubo, S. Yla-Herttuala, M. Jaattela, and K. Alitalo Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth Cancer Research 61 2001 1786 1790 (Pubitemid 32691984)
25. S.J. Mandriota, L. Jussila, M. Jeltsch, A. Compagni, D. Baetens, R. Prevo, S. Banerji, J. Huarte, R. Montesano, D.G. Jackson, L. Orci, K. Alitalo, G. Christofori, and M.S. Pepper Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis The EMBO Journal 20 2001 672 682 (Pubitemid 32167632)
26. Z. Von Marschall, A. Scholz, S.A. Stacker, M.G. Achen, D.G. Jackson, F. Alves, M. Schirner, M. Haberey, K.H. Thierauch, B. Wiedenmann, and S. Rosewicz Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer International Journal of Oncology 27 2005 669 679
27. S.A. Stacker, C. Caesar, M.E. Baldwin, G.E. Thornton, R.A. Williams, R. Prevo, D.G. Jackson, S. Nishikawa, H. Kubo, and M.G. Achen VEGF-D promotes the metastatic spread of tumor cells via the lymphatics Nature Medicine 7 2001 186 191 (Pubitemid 32148485)
28. M.G. Achen, G.B. Mann, and S.A. Stacker Targeting lymphangiogenesis to prevent tumour metastasis British Journal of Cancer 94 2006 1355 1360 (Pubitemid 43772266)
29. C.A. Garces, E.V. Kurenova, V.M. Golubovskaya, and W.G. Cance Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells Cancer Research 66 2006 1446 1454 (Pubitemid 43259925)
30. M.R. Arkin, and J.A. Wells Small-molecule inhibitors of protein-protein interactions: progressing towards the dream Nature Reviews. Drug Discovery 3 2004 301 317 (Pubitemid 38499758)
31. E.V. Kurenova, D.L. Hunt, D. He, A.T. Magis, D.A. Ostrov, and W.G. Cance Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo Journal of Medicinal Chemistry 52 2009 4716 4724
32. E. Kurenova, J. Liao, D.H. He, D. Hunt, M. Yemma, W. Bshara, M. Seshadri, and W.G. Cance The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth Oncotarget 4 2013 1632 1646
33. M.M. Hann, and T.I. Oprea Pursuing the leadlikeness concept in pharmaceutical research Current Opinion in Chemical Biology 8 2004 255 263 (Pubitemid 38759400)
34. E.V. Kurenova, D.L. Hunt, D. He, A.D. Fu, N.A. Massoll, V.M. Golubovskaya, C.A. Garces, and W.G. Cance Vascular endothelial growth factor receptor-3 promotes breast cancer cell proliferation, motility and survival in vitro and tumor formation in vivo Cell Cycle 8 2009
35. S.K. Mitra, D. Mikolon, J.E. Molina, D.A. Hsia, D.A. Hanson, A. Chi, S.T. Lim, J.A. Bernard-Trifilo, D. Ilic, D.G. Stupack, D.A. Cheresh, and D.D. Schlaepfer Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors Oncogene 25 2006 5969 5984 (Pubitemid 44477291)
36. T.B. Deramaudt, D. Dujardin, A. Hamadi, F. Noulet, K. Kolli, J. De Mey, K. Takeda, and P. Ronde FAK phosphorylation at Tyr925 regulates crosstalk between focal adhesion turnover and cell protrusion Molecular Biology of the Cell 22 7 2011 964 975 mbc.E10-08-0725
37. Y. Abdiche, D. Malashock, A. Pinkerton, and J. Pons Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet Analytical Biochemistry 377 2008 209 217
38. C.A. Belmokhtar, J. Hillion, and E. Segal-Bendirdjian Staurosporine induces apoptosis through both caspase-dependent and caspase-independent mechanisms Oncogene 20 2001 3354 3362 (Pubitemid 32588984)
39. C.G. Wilson, and M.R. Arkin Small-molecule inhibitors of IL-2/IL-2R: lessons learned and applied Current Topics in Microbiology and Immunology 348 2011 25 59
40. T. Oltersdorf, S.W. Elmore, A.R. Shoemaker, R.C. Armstrong, D.J. Augeri, B.A. Belli, M. Bruncko, T.L. Deckwerth, J. Dinges, P.J. Hajduk, M.K. Joseph, S. Kitada, S.J. Korsmeyer, A.R. Kunzer, A. Letai, C. Li, M.J. Mitten, D.G. Nettesheim, S. Ng, P.M. Nimmer, J.M. O'Connor, A. Oleksijew, A.M. Petros, J.C. Reed, W. Shen, S.K. Tahir, C.B. Thompson, K.J. Tomaselli, B. Wang, M.D. Wendt, H. Zhang, S.W. Fesik, and S.H. Rosenberg An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 435 2005 677 681 (Pubitemid 40825512)
41. L.T. Vassilev, B.T. Vu, B. Graves, D. Carvajal, F. Podlaski, Z. Filipovic, N. Kong, U. Kammlott, C. Lukacs, C. Klein, N. Fotouhi, and E.A. Liu In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 303 2004 844 848 (Pubitemid 38174664)
42. E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, and T.E. Ferrin UCSF Chimera-a visualization system for exploratory research and analysis Journal of Computational Chemistry 25 2004 1605 1612
43. S.T. Arold, M.K. Hoellerer, and M.E. Noble The structural basis of localization and signaling by the focal adhesion targeting domain Structure 10 2002 319 327 (Pubitemid 34230620)